• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Prosensa

edit

Prosensa is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.

During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology.

Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Recent Milestones

edit

• 
  Prosensa received $29.8M (€23M) in Venture Round funding. (1/25/12)
  Posted 1/25/12 at 4:05am via reuters.com
• 
  Prosensa received $25.3M (€18M) in Series B funding. (12/17/08)
  Posted 6/15/09 at 3:16am via regiovizier.nl
• 
  Prosensa added Hans GCP Schikan as Chief Executive Officer.
  Posted 6/15/09 at 3:18am
• 
  Prosensa added Gerard Platenburg as Chief Development Officer.
  Posted 6/15/09 at 3:18am
• 
  Prosensa added Roelck A Cuperus as VP Regulatory Affairs.
  Posted 6/15/09 at 3:18am

Videos

Screenshots

edit

Above: Prosensa
Uploaded: 6/15/09

Sources

1. Prosensa raises EUR 18 million Series B financing (hollandrijnland.regiovizier.nl) [edit]
2. Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates (reuters.com) [edit]